Nasdaq Stockholm

ACTI

Tasquinimod

Laquinimod

Naptumomab

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in hematological cancers, non-infectious uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Latest News

Financial Calendar

Interim Report Jan-Jun 2025

Date: August 21, 2025

Events

No events are found.

Pipeline

Fully owned projects

Disease Area

Discovery

Preclinical

Phase I

Phase II

Phase III

Partner

Hematological malignancies

Tasquinimod Multiple myeloma*

Tasquinimod Myelofibrosis

Inflammatory eye disorders

Laquinimod eye drops, safety and tolerability

Laquinimod eye drops, ocular biodistribution

Study ongoing

* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Licensed projects

Disease Area

Discovery

Preclinical

Phase I

Phase II

Phase III

Partner

Solid tumors

Naptumomab Combination with docetaxel in non-small cell lung cancer

Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod

Cookie	Duration	Description
cookielawinfo-checkbox-functional	12 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". It does not store any personal data.
cookielawinfo-checkbox-necessary	12 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". It does not store any personal data.
CookieLawInfoConsent	12 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy	12 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma

Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe

Redeye interview with CEO Helén Tuvesson and CMO Erik Vahtola (in Swedish)

Active Biotech Interim Report Q1 2025

Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye

Notice of annual general meeting

Annual Report 2024 Active Biotech AB (publ)

Interview with Lucia Masarova, Assistant Professor at MD Anderson Cancer Center

First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US

First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis

Infocus interview with CEO Helen Tuvesson at Redeye Technology & Life Science Day 2024

Active Biotech’s patent for laquinimod in eye disorders will be granted in the US

Aktiespararna: Active Biotech: Sikte på avtal nästa år (in Swedish)

European Patent Office has granted Active Biotech’s patent application for eye drop formulation of laquinimod

Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops

Investor Relations

Projects

Annual Report 2024